Trial Profile
A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibrate 160mg/Pravastatin 40mg combination versus Simvastatin 20mg in patients without Cardiovascular disease (CVD) (group 1) and of Fenofibrate 160mg/Pravastatin 40mg combination+Ezetimibe 10mg versus Simvastatin 20mg+Ezetimibe 10mg in patients with CVD (group 2), followed by a 12-week safety phase of Fenofibrate 160mg/Pravastatin 40mg combination in group 1 and of Fenofibrate 160mg/Pravastatin 40 mg combination+Ezetimibe 10mg in group 2.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Fenofibrate/pravastatin (Primary) ; Simvastatin
- Indications Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms PREFED
- Sponsors SMB
- 05 Jul 2012 Actual end date (7 Sep 2008) added as reported by European Clinical Trials Database.
- 05 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2006-006557-28).
- 05 Jul 2012 Planned number of patients 480, additional drug company, trial locations, actual initiation date (7 May 2007) added and official title amended as reported by European Clinical Trials Database.